Integrated Perspectives on Vascular Liver Disorders

Description

This session encompasses basic, translational, and clinical studies in vascular liver disease and portal hypertension, ranging from congestive hepatopathy and cirrhosis in Fontan-associated liver disease to intrahepatic moecular pathways of fibrosis in chronic liver disease. Key areas also include examination of porto-sinusoidal vascular liver disease and TIPS for acute and chronic portal vein thrombosis. 

Presentations

2:00 PM - 2:15 PM
Aug 05 2026
Convention Center - Room 146A, Level 1

Metabolic Reprogramming of Glutamine–Glutamate Axis in Fontan-Associated Liver Disease (FALD) 

Justin Boike, MD, MPH , Abstract Presenter
Cirrhosis and Portal Hypertension
2:15 PM - 2:30 PM
Aug 05 2026
Convention Center - Room 146A, Level 1

YAP contributes to liver fibrosis through mediating capillarization of liver sinusoidal endothelial cells via GATA6/eNOS signaling

Elizabeth C Verna, MD, MS, FAASLD , Abstract Presenter
Cirrhosis and Portal Hypertension
2:30 PM - 2:45 PM
Aug 05 2026
Convention Center - Room 146A, Level 1

Association between Liver Related Factors and Post- Cardiac Surgery Mortality

Riccardo Superina, MD , Abstract Presenter
Cirrhosis and Portal Hypertension
2:45 PM - 3:00 PM
Aug 05 2026
Convention Center - Room 146A, Level 1

Role for Endokyne-1 in LSEC–HSC communication and its association with advanced chronic liver disease

Justin Boike, MD, MPH , Abstract Presenter
Cirrhosis and Portal Hypertension
3:00 PM - 3:15 PM
Aug 05 2026
Convention Center - Room 146A, Level 1

Outcomes and Patency of TIPS for Portal Vein Thrombosis from the ALTA Study Group

Justin Boike, MD, MPH , Abstract Presenter
Cirrhosis and Portal Hypertension
3:15 PM - 3:30 PM
Aug 05 2026
Convention Center - Room 146A, Level 1

Clinical Characteristics and Influential Factors of Porto-Sinusoidal Vascular Disease with Portal Hypertension

Riccardo Superina, MD , Abstract Presenter
Cirrhosis and Portal Hypertension

Objectives

  • Describe molecular mechanisms of fibrosis in vascular and chronic liver disease.
  • Discuss mechanisms of hepatopathy in Fontan-associated liver disease as well as clinical implications after cardiac surgery.
  • Evaluate the interactions of vascular liver disorders and portal hypertension, including the role of TIPS.